Alexandra Pohl1, Roland Kappler1, Jakob Mühling1, Dietrich VON Schweinitz1, Michael Berger2. 1. Department of Pediatric Surgery, Dr von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. 2. Department of Pediatric Surgery, Dr von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany michael.fabian.berger@gmail.com.
Abstract
BACKGROUND: Neuroblastoma is an embryonal malignancy arising from the aberrant growth of neural crest progenitor cells of the sympathetic nervous system. The tachykinin receptor 1 (TACR1) - substance P complex is associated with tumoral angiogenesis and cell proliferation in a variety of cancer types. Inhibition of TACR1 was recently described to impede growth of NB cell lines. However, the relevance of TACR1 in clinical settings is unknown. PATIENTS AND METHODS: We investigated gene expression levels of full-length and truncated TACR1 in 59 neuroblastomas and correlated these data with the patients' clinical parameters such as outcome, metastasis, International Neuroblastoma Staging System (INSS) status, MYCN proto-oncogene, bHLH transcription factor (MYCN) status, gender and age. RESULTS: Our results indicated that TACR1 is ubiquitously expressed in neuroblastoma but expression levels are independent of clinical parameters. CONCLUSION: Our data suggest that TACR1 might serve as a potent anticancer target in a large variety of patients with neuroblastoma, independent of tumor biology and clinical stage. Copyright
BACKGROUND:Neuroblastoma is an embryonal malignancy arising from the aberrant growth of neural crest progenitor cells of the sympathetic nervous system. The tachykinin receptor 1 (TACR1) - substance P complex is associated with tumoral angiogenesis and cell proliferation in a variety of cancer types. Inhibition of TACR1 was recently described to impede growth of NB cell lines. However, the relevance of TACR1 in clinical settings is unknown. PATIENTS AND METHODS: We investigated gene expression levels of full-length and truncated TACR1 in 59 neuroblastomas and correlated these data with the patients' clinical parameters such as outcome, metastasis, International Neuroblastoma Staging System (INSS) status, MYCN proto-oncogene, bHLH transcription factor (MYCN) status, gender and age. RESULTS: Our results indicated that TACR1 is ubiquitously expressed in neuroblastoma but expression levels are independent of clinical parameters. CONCLUSION: Our data suggest that TACR1 might serve as a potent anticancer target in a large variety of patients with neuroblastoma, independent of tumor biology and clinical stage. Copyright
Authors: Mario F Muñoz; Sandro Argüelles; Marisa Rosso; Rafael Medina; Rafael Coveñas; Antonio Ayala; Miguel Muñoz Journal: Biomed Res Int Date: 2022-04-04 Impact factor: 3.246
Authors: Julian Kolorz; Salih Demir; Adrian Gottschlich; Iris Beirith; Matthias Ilmer; Daniel Lüthy; Christoph Walz; Mario M Dorostkar; Thomas Magg; Fabian Hauck; Dietrich von Schweinitz; Sebastian Kobold; Roland Kappler; Michael Berger Journal: Curr Oncol Date: 2021-12-26 Impact factor: 3.677